News
HYPMY
4.390
-0.45%
-0.020
Hypera upgraded to Buy from Neutral at Goldman Sachs
TipRanks · 08/17 11:07
Hypera S.A. Earnings Call Shows Profitable Growth
TipRanks · 08/08 00:25
Hypera S.A. (HYPE3) Gets a Buy from Jefferies
TipRanks · 07/20 06:55
Hypera initiated with a Buy at Jefferies
TipRanks · 07/19 18:15
Positive Report for Hypera S.A. (HYPE3) from Citi
TipRanks · 05/15 10:27
Hypera upgraded to Buy from Neutral at Citi
TipRanks · 05/15 09:50
Scotiabank Sticks to Its Buy Rating for Hypera S.A. (HYPE3)
TipRanks · 04/29 16:45
Hypera Q1 EPS $0.10 Up From $(0.04) YoY, Sales $383.213M Up From $184.571M YoY
Benzinga · 04/28 22:04
Scotiabank Reaffirms Their Buy Rating on Hypera S.A. (HYPE3)
TipRanks · 03/16 08:45
Hypera S.A. Reports Strong Earnings Amid Challenges
TipRanks · 10/31/2025 00:10
Weekly Report: what happened at HYPMY last week (0908-0912)?
Weekly Report · 09/15/2025 11:15
More
Webull provides a variety of real-time HYPMY stock news. You can receive the latest news about Hypera Sa through multiple platforms. This information may help you make smarter investment decisions.
About HYPMY
Hypera SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company operates in several markets with a variety of pharmaceutical products. The Company's products include: Mantecorp Farmasa, which is an under the umbrella brand; Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador, and Rinosoro, which focus on several medical specialties involving primary care which are present in main therapeutic classes; Mantecorp Skincare, which offer dermo cosmetics recommended by dermatologists and also operates in this segment with the brands Simple Organic, which offers organic, vegan, and cruelty-free products, and Bioage, which focuses on the professional aesthetic treatment market; and Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina, which are over-the-counter medications provided throughout Brazil.